参芪扶正联合放疗治疗非小细胞肺癌的荟萃分析。

A meta-analysis of Shenqi Fuzheng combined with radiation in the treatment of nonsmall cell lung cancer.

作者信息

Jiang Huijuan, Zhang Hongzhi, Hu Xigang, Ma Jing

机构信息

Department of Radiotherapy, Huaihe Hospital of Henan University, Henan, Kaifeng 475000, China.

出版信息

J Cancer Res Ther. 2015 Aug;11 Suppl 1:C101-3. doi: 10.4103/0973-1482.163855.

DOI:10.4103/0973-1482.163855

PMID:26323903

Abstract

OBJECTIVE

The objective of this study is to evaluate the efficacy and toxicity reduction of Shenqi Fuzheng injection in the treatment of nonsmall cell lung cancer (NSCLC).

MATERIALS AND METHODS

Through searching the PubMed, WANFANG and CNKI, we recruited clinical trials related to Shenqi Fuzheng combined with radiation in the treatment of NSCLC. We extracted the treatment effective data and radiation related toxicities data. The clinical efficacy and radiation toxicity was pooled by meta-analysis. The statistical heterogeneity was evaluated by I 2 tests.

RESULTS

By searching the related databases, we finally included 7 studies in this meta-analysis. The pooled results indicated that Shenqi Fuzheng injection can improve the clinical efficacy (relative risk [RR] =1.27, 95% confidence interval [CI]: 1.13-1.43), and decrease the radiation pneumonia (RR = 0.41, 95% CI: 0.26-0.46), radiation esophagitis (RR = 0.46, 95% CI: 0.37-0.59) and bone marrow suppression (RR = 0.44, 95% CI: 0.36-0.53).

CONCLUSION

Shenqi Fuzheng injection can improve the clinical efficacy and decrease the radiation toxicities in the NSCLC patients treated with radiation.

摘要

目的

本研究旨在评估参芪扶正注射液在治疗非小细胞肺癌（NSCLC）中的疗效及降低毒性的作用。

材料与方法

通过检索PubMed、万方和知网，我们纳入了参芪扶正联合放疗治疗NSCLC的临床试验。我们提取了治疗有效数据和放疗相关毒性数据。通过Meta分析汇总临床疗效和放疗毒性。采用I²检验评估统计异质性。

结果

通过检索相关数据库，我们最终在本Meta分析中纳入了7项研究。汇总结果表明，参芪扶正注射液可提高临床疗效（相对危险度[RR]=1.27，95%置信区间[CI]：1.13-1.43），并降低放射性肺炎（RR=0.41，95%CI：0.26-0.46）、放射性食管炎（RR=0.46，95%CI：0.37-0.59）和骨髓抑制（RR=0.44，95%CI：0.36-0.53）的发生率。